CLVS Clovis Oncology, Inc. Stock Quote

CLVS [NASD]

Index	-	P/E	-	EPS (ttm)	-5.24	Insider Own	0.50%	Shs Outstand	88.26M	Perf Week	8.90%
Market Cap	577.36M	Forward P/E	-	EPS next Y	-2.47	Insider Trans	-5.42%	Shs Float	86.48M	Perf Month	21.19%
Income	-369.80M	PEG	-	EPS next Q	-0.78	Inst Own	67.10%	Short Float	42.43%	Perf Quarter	2.09%
Sales	160.50M	P/S	3.60	EPS this Y	-5.20%	Inst Trans	8.60%	Short Ratio	7.38	Perf Half Y	-4.67%
Book/sh	-1.85	P/B	-	EPS next Y	38.80%	ROA	-59.30%	Target Price	7.33	Perf Year	-37.87%
Cash/sh	2.38	P/C	2.57	EPS next 5Y	78.90%	ROE	263.20%	52W Range	3.62 - 11.63	Perf YTD	27.50%
Dividend	-	P/FCF	-	EPS past 5Y	-9.50%	ROI	-76.50%	52W High	-42.48%	Beta	1.89
Dividend %	-	Quick Ratio	2.10	Sales past 5Y	60.00%	Gross Margin	75.30%	52W Low	84.80%	ATR	0.41
Employees	484	Current Ratio	2.30	Sales Q/Q	3.20%	Oper. Margin	-	RSI (14)	69.25	Volatility	9.88% 7.59%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	48.20%	Profit Margin	-	Rel Volume	1.95	Prev Close	6.12
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 05 BMO	Payout	-	Avg Volume	4.97M	Price	6.69
Recom	3.30	SMA20	29.74%	SMA50	37.68%	SMA200	8.68%	Volume	7,910,510	Change	9.31%

May-18-20

Reiterated

H.C. Wainwright

Buy

$29 → $33

Apr-27-20

Downgrade

SVB Leerink

Mkt Perform → Underperform

Apr-09-20

Downgrade

BofA/Merrill

Neutral → Underperform

Jan-08-20

Reiterated

H.C. Wainwright

Buy

$36 → $27

Nov-19-19

Downgrade

Evercore ISI

Outperform → In-line

Sep-24-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

$22 → $10

Aug-13-19

Downgrade

BofA/Merrill

Buy → Neutral

Aug-02-19

Downgrade

Guggenheim

Buy → Neutral

May-29-19

Downgrade

Goldman

Neutral → Sell

Apr-15-19

Reiterated

H.C. Wainwright

Buy

$39 → $37

Feb-13-19

Initiated

H.C. Wainwright

Buy

$40

Dec-04-18

Upgrade

Leerink Partners

Mkt Perform → Outperform

Oct-31-18

Downgrade

JP Morgan

Overweight → Neutral

Oct-19-18

Resumed

Piper Jaffray

Neutral

Sep-25-18

Initiated

Leerink Partners

Mkt Perform

Feb-22-18

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

Feb-22-18

Upgrade

Evercore ISI

In-line → Outperform

Oct-23-17

Initiated

Barclays

Overweight

$105

Sep-15-17

Initiated

RBC Capital Mkts

Sector Perform

$81

Aug-17-17

Initiated

Evercore ISI

In-line

$73

Jan-11-21 08:00AM	Clovis Oncology Announces Preliminary Product Revenues for the Fourth Quarter and Full Year 2020 Business Wire +11.29%
Dec-30-20 06:49AM	Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug Zacks +10.56%
Dec-29-20 08:00AM	Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial Business Wire
Dec-22-20 10:28AM	Company News for Dec 22, 2020 Zacks
10:05AM	Clovis' (CLVS) Rubraca Confirmatory Study Meets Endpoint Zacks
Dec-21-20 10:05AM	Looking Into Clovis Oncology's Return On Capital Employed Benzinga +7.04%
08:00AM	Clovis Oncologys Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation Business Wire
Dec-16-20 10:51PM	Is CLVS A Good Stock To Buy Now? Insider Monkey
Dec-10-20 08:55AM	Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks
Dec-05-20 11:32AM	Clovis (CLVS) Up 18.6% Since Last Earnings Report: Can It Continue? Zacks
Nov-24-20 06:06PM	Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Companys 4.50% Convertible Senior Notes Due 2024 Business Wire +5.02%
Nov-20-20 08:00AM	Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference Business Wire
Nov-08-20 07:40AM	Clovis Oncology, Inc. (NASDAQ:CLVS) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Nov-06-20 10:43AM	Clovis (CLVS) Q3 Earnings Top, Sales Show Coronavirus Impact Zacks
Nov-05-20 09:25AM	Clovis Oncology (CLVS) Reports Q3 Loss, Lags Revenue Estimates Zacks -21.16%
08:05AM	Clovis Oncology Announces Third Quarter 2020 Operating Results Business Wire
08:02AM	Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes Business Wire
Oct-29-20 12:35PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-20-20 04:05PM	Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5 Business Wire
Oct-14-20 10:15PM	Hedge Funds Are Dipping Their Toes Back Into Clovis Oncology Inc (CLVS) Insider Monkey -6.24%
Oct-13-20 06:47AM	How Much Is Clovis Oncology, Inc. (NASDAQ:CLVS) Paying Its CEO? Simply Wall St. +15.70%
Sep-17-20 03:05AM	New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline Business Wire
Sep-10-20 08:05AM	Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting Business Wire +5.63%
Sep-09-20 08:05AM	Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 Business Wire
Sep-08-20 04:19PM	Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Business Wire
08:53AM	Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock? Zacks
Sep-05-20 11:31AM	Clovis (CLVS) Down 17.3% Since Last Earnings Report: Can It Rebound? Zacks
Aug-27-20 09:58AM	ROCE Insights For Clovis Oncology Benzinga
08:02AM	The Daily Biotech Pulse: Liver Congress Underway, FDA Approves Companion Diagnostic Test For Clovis Cancer Drug, EUA For Abbott's $5, 15-Minute COVID-19 Test Benzinga
Aug-26-20 07:23PM	FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Business Wire
Aug-18-20 10:36AM	Return On Capital Employed Overview: Clovis Oncology Benzinga
Aug-17-20 03:13PM	Why Clovis Oncology's Stock Is Trading Higher Today Benzinga +20.12%
08:05AM	Journal of Clinical Oncology Publishes Additional Data from Clovis Oncologys TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations Business Wire
Aug-07-20 11:44AM	Clovis (CLVS) Q2 Earnings Lag, Revenues Show Coronavirus Impact Zacks -13.00%
Aug-06-20 07:10PM	Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:05PM	Clovis Oncology Announces Second Quarter 2020 Operating Results Business Wire
Aug-05-20 08:05AM	Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers Business Wire
Jul-30-20 12:33PM	Clovis Oncology (CLVS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Jul-23-20 08:00AM	Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6 Business Wire +5.48%
Jul-21-20 12:00PM	Clovis (CLVS) Upgraded to Buy: Here's Why Zacks
Jul-15-20 09:17AM	Have Insiders Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares? Simply Wall St.
Jun-30-20 02:46PM	Hedge Funds Never Been Less Bullish On Clovis Oncology Inc (CLVS) Insider Monkey
Jun-23-20 08:37AM	Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now? Zacks
Jun-22-20 09:01AM	New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II PR Newswire +9.30%
Jun-17-20 08:00AM	Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020 Business Wire -5.24%
Jun-11-20 10:49AM	Clovis Completes Enrollment in Late-Stage Ovarian Cancer Study Zacks -7.70%
08:12AM	The Daily Biotech Pulse: Sorrento Submits EUA Application For Rapid Coronavirus Test, Decision Day For Viela, Lantern Pharma IPO Benzinga
Jun-10-20 04:05PM	Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer Business Wire
Jun-04-20 11:31AM	Why Is Clovis (CLVS) Down 17.2% Since Last Earnings Report? Zacks
May-28-20 08:00AM	Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Business Wire
05:06AM	Edited Transcript of CLVS earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-21-20 04:10PM	Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program Business Wire
02:24PM	Clovis Oncology Needs a Savior GuruFocus.com
May-19-20 06:53PM	8 Biotechs Tapping Secondary Markets for $3 Billion GuruFocus.com -16.07%
03:09PM	Why Clovis Oncology's Stock Is Trading Lower Today Benzinga
May-18-20 08:05PM	Clovis Oncology Announces Pricing of Public Offering of Common Stock Business Wire -7.53%
04:02PM	Clovis Oncology Announces Proposed Offering of Common Stock Business Wire
11:45AM	Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer Zacks
May-16-20 11:31AM	Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer Motley Fool
May-15-20 02:30PM	Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy Business Wire
May-14-20 10:18AM	Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now? Zacks
May-11-20 11:00AM	Why Clovis Oncology Stock Marched Higher in April Motley Fool
May-06-20 11:17AM	Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates Zacks
11:02AM	Clovis Oncology (CLVS) Q1 2020 Earnings Call Transcript Motley Fool
08:02AM	Benzinga Pro's Top 5 Stocks To Watch for Wed., May 6, 2020: SNY, GRUB, CLVS, NTDOY, FDS Benzinga
May-05-20 07:05PM	Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Clovis Oncology Announces First Quarter 2020 Operating Results Business Wire
May-03-20 09:25AM	Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Benzinga
Apr-29-20 04:05PM	Clovis Oncology to Present at the Bank of America Health Care Conference 2020 Business Wire
Apr-28-20 12:34PM	Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-22-20 09:00AM	Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock? Zacks
Apr-21-20 04:05PM	Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5 Business Wire
Apr-15-20 12:00PM	Clovis (CLVS) Upgraded to Buy: Here's Why Zacks
Apr-14-20 05:08PM	Clovis Oncology Announces Debt Exchange Transaction Business Wire
Apr-09-20 10:04AM	Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca Benzinga
Apr-03-20 05:50PM	Clovis Oncology (CLVS) Gains As Market Dips: What You Should Know Zacks
Mar-25-20 11:30AM	Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report? Zacks -5.14%
Mar-20-20 09:36AM	Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks
Mar-19-20 05:50PM	Clovis Oncology (CLVS) Gains But Lags Market: What You Should Know Zacks
Mar-11-20 05:50PM	Clovis Oncology (CLVS) Stock Moves -1.59%: What You Should Know Zacks
Mar-03-20 08:30AM	Clovis Oncology to Present at the Barclays Global Healthcare Conference Business Wire
Mar-02-20 04:00AM	Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain Business Wire
Feb-27-20 07:24AM	Edited Transcript of CLVS earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -8.49%
Feb-26-20 09:02AM	Here's What Analysts Are Forecasting For Clovis Oncology, Inc. After Its Full-Year Results Simply Wall St. -6.38%
Feb-25-20 10:12AM	Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat Zacks -19.46%
Feb-24-20 06:15PM	Clovis Oncology (CLVS) Reports Q4 Loss, Tops Revenue Estimates Zacks -9.82%
04:05PM	Clovis Oncology Announces 2019 Operating Results Business Wire
Feb-21-20 11:30AM	Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year? Zacks
Feb-19-20 10:13AM	What's in Store for Aimmune (AIMT) This Earnings Season? Zacks +12.96%
09:39AM	Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4? Zacks
08:39AM	Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Feb-17-20 12:30PM	Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
08:46AM	5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates Zacks
Feb-13-20 08:30AM	Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24 Business Wire
Feb-11-20 04:05PM	Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference Business Wire
Feb-06-20 03:34PM	4 Stocks Looking Higher During Earnings Season Benzinga
11:17AM	Four stocks to watch this week include Clovis Oncology and 3D Systems MarketWatch
Feb-03-20 09:44AM	Is a Beat in the Cards for Humana's (HUM) Earnings in Q4? Zacks
04:00AM	Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France Business Wire
Jan-31-20 08:16AM	Have Insiders Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares? Simply Wall St.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rolfe Lindsey	See Remarks	Dec 21	Sale	5.68	1,728	9,815	58,275	Dec 23 04:52 PM
IVERS-READ GILLIAN C	See Remarks	Dec 21	Sale	5.68	829	4,709	233,086	Dec 23 04:51 PM
Rolfe Lindsey	See Remarks	Dec 15	Option Exercise	3.28	17,241	56,550	70,718	Dec 16 04:15 PM
IVERS-READ GILLIAN C	See Remarks	Dec 10	Option Exercise	3.28	68,965	226,205	284,487	Dec 14 04:20 PM
Harding Thomas C.	See Remarks	Dec 03	Sale	4.89	188	919	3,378	Dec 07 09:52 PM
Gross Paul Edward	See Remarks	Dec 03	Sale	4.89	457	2,235	30,380	Dec 07 09:46 PM
Rolfe Lindsey	See Remarks	Dec 03	Sale	4.89	661	3,232	53,136	Dec 07 09:45 PM
IVERS-READ GILLIAN C	See Remarks	Dec 03	Sale	4.89	581	2,841	215,139	Dec 07 09:42 PM
MUEHL DANIEL W	See Remarks	Dec 03	Sale	4.89	457	2,235	34,424	Dec 07 09:42 PM
ATWOOD BRIAN G	Director	Nov 09	Option Exercise	3.08	6,896	21,240	32,758	Nov 10 07:39 PM
MUEHL DANIEL W	See Remarks	Nov 03	Sale	4.93	2,534	12,493	32,478	Nov 05 04:17 PM
Gross Paul Edward	See Remarks	Nov 03	Sale	4.93	1,152	5,679	28,434	Nov 05 04:17 PM
IVERS-READ GILLIAN C	See Remarks	Nov 03	Sale	4.93	1,689	8,327	214,791	Nov 05 04:18 PM
Rolfe Lindsey	See Remarks	Nov 03	Sale	4.93	1,920	9,466	52,826	Nov 05 04:18 PM
Rolfe Lindsey	See Remarks	Sep 21	Sale	6.85	1,747	11,967	50,997	Sep 23 04:36 PM
IVERS-READ GILLIAN C	See Remarks	Sep 21	Sale	6.85	838	5,740	212,731	Sep 23 04:31 PM
Gross Paul Edward	See Remarks	Sep 03	Sale	5.30	435	2,306	26,704	Sep 08 04:22 PM
IVERS-READ GILLIAN C	See Remarks	Sep 03	Sale	5.30	553	2,931	211,296	Sep 08 04:19 PM
MUEHL DANIEL W	See Remarks	Sep 03	Sale	5.30	435	2,306	30,748	Sep 08 04:16 PM
Rolfe Lindsey	See Remarks	Sep 03	Sale	5.30	628	3,328	48,948	Sep 08 04:15 PM
MUEHL DANIEL W	See Remarks	Aug 26	Sale	5.07	242	1,227	30,477	Aug 27 04:16 PM
Gross Paul Edward	See Remarks	Aug 03	Sale	5.92	2,506	14,836	24,732	Aug 05 05:01 PM
IVERS-READ GILLIAN C	See Remarks	Aug 03	Sale	5.92	1,670	9,886	210,934	Aug 05 05:00 PM
MUEHL DANIEL W	See Remarks	Aug 03	Sale	5.92	2,506	14,836	28,471	Aug 05 05:00 PM
Rolfe Lindsey	See Remarks	Aug 03	Sale	5.92	1,899	11,242	48,622	Aug 05 05:00 PM
Gross Paul Edward	See Remarks	Aug 03	Sale	4.93	1,382	6,813	30,119	Nov 05 04:17 PM
Rolfe Lindsey	See Remarks	Jun 22	Sale	6.74	1,728	11,647	46,772	Jun 23 05:16 PM
IVERS-READ GILLIAN C	See Remarks	Jun 22	Sale	6.74	829	5,587	208,855	Jun 23 05:15 PM
Gross Paul Edward	See Remarks	Jun 03	Sale	7.03	470	3,304	23,009	Jun 05 05:00 PM
IVERS-READ GILLIAN C	See Remarks	Jun 03	Sale	7.03	598	4,204	207,435	Jun 05 05:00 PM
Rolfe Lindsey	See Remarks	Jun 03	Sale	7.03	680	4,780	44,731	Jun 05 04:51 PM
MUEHL DANIEL W	See Remarks	Jun 03	Sale	7.03	470	3,304	26,748	Jun 05 04:49 PM
MUEHL DANIEL W	See Remarks	May 27	Sale	6.91	247	1,707	26,494	May 28 07:41 PM
Gross Paul Edward	See Remarks	May 05	Sale	8.10	2,213	17,925	20,895	May 07 04:45 PM
IVERS-READ GILLIAN C	See Remarks	May 05	Sale	8.10	1,475	11,948	207,095	May 07 04:16 PM
MUEHL DANIEL W	See Remarks	May 05	Sale	8.10	2,213	17,925	24,334	May 07 04:15 PM
Rolfe Lindsey	See Remarks	May 05	Sale	8.10	1,677	13,584	44,430	May 07 04:15 PM
Rolfe Lindsey	See Remarks	Apr 06	Option Exercise	3.08	23,034	70,945	59,091	Apr 08 04:00 PM
IVERS-READ GILLIAN C	See Remarks	Mar 20	Sale	4.60	829	3,813	204,821	Mar 23 04:44 PM
Rolfe Lindsey	See Remarks	Mar 20	Sale	4.60	1,728	7,949	36,057	Mar 23 04:42 PM
IVERS-READ GILLIAN C	See Remarks	Mar 03	Sale	7.20	605	4,356	203,404	Mar 05 04:17 PM
MUEHL DANIEL W	See Remarks	Mar 03	Sale	7.20	475	3,420	22,480	Mar 05 04:17 PM
Gross Paul Edward	See Remarks	Mar 03	Sale	7.20	475	3,420	19,041	Mar 05 04:15 PM
Rolfe Lindsey	See Remarks	Mar 03	Sale	7.20	687	4,946	34,020	Mar 05 04:16 PM
MUEHL DANIEL W	See Remarks	Feb 27	Sale	6.90	279	1,925	22,227	Mar 02 04:17 PM
MUEHL DANIEL W	See Remarks	Feb 04	Sale	8.41	10,472	88,070	15,117	Feb 06 04:19 PM
IVERS-READ GILLIAN C	See Remarks	Feb 04	Sale	8.41	7,204	60,586	203,067	Feb 06 04:16 PM
Rolfe Lindsey	See Remarks	Feb 04	Sale	8.41	7,503	63,100	33,722	Feb 06 04:15 PM
Gross Paul Edward	See Remarks	Feb 04	Sale	8.41	10,470	88,053	11,944	Feb 06 04:15 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience